Status of 10 targeted genes of non‐small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution

Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line

(2020) Yoshinori Tsukumo et al.   PLoS One

Treatment outcome and clinical characteristics of HER2 mutated advanced non‐small cell lung cancer patients in China

(2020) Fei Xu et al.   Thoracic Cancer

Clinicopathological Features of ALK Expression in 9889 Cases of Non-small-Cell Lung Cancer and Genomic Rearrangements Identified by Capture-Based Next-Generation Sequencing: A Chinese Retrospective Analysis

(2019) Ruiying Zhao et al.   Molecular Diagnosis & Therapy

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

(2019) Badi El Osta et al.   Journal of Thoracic Oncology

Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer

(2019) Chen Lin et al.   LUNG CANCER

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR , ALK , ROS1 , KRAS or BRAF

(2019) Xibin Zhuang et al.   Cancer Medicine

The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients

(2019) Quan Lin et al.   Journal of Translational Medicine

Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer

(2019) Xuejuan Gao et al.   Cancer Management and Research

Epidermal growth factor receptor first generation tyrosine-kinase inhibitors

(2019) Alex Martinez-Marti et al.   Translational Lung Cancer Research

Worldwide Frequency of Commonly Detected EGFR Mutations

(2018) Rondell P. Graham et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment

(2018) Weihua Li et al.   CANCER LETTERS

Targeted Therapy for Patients With Metastatic Non–Small Cell Lung Cancer

(2018) Karen L. Reckamp   Journal of the National Comprehensive Cancer Network

GOPC - ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma

(2018) Liang Zeng et al.   Journal of Thoracic Oncology

Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma

(2018) Mengnan Zhao et al.   Journal of Thoracic Disease

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation

(2018) Shuyuan Wang et al.   INTERNATIONAL JOURNAL OF CANCER

Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

(2018) Hmwe Hmwe Kyu et al.   LANCET

Clinical Outcome of ALK -Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)

(2017) Sabine Schmid et al.   Journal of Thoracic Oncology

Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib

(2017) Sai-Hong Ignatius Ou et al.   LUNG CANCER

Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma

(2017) Zhenya Tang et al.   MODERN PATHOLOGY

Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy

(2017) Motonobu Saito et al.   SURGERY TODAY

Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer

(2017) Wentao Hu et al.   Oncotarget

Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer

(2017) Jianping Xu et al.   Cancer Biomarkers

Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer

(2016) Shi Bu et al.   ANNALS OF SURGICAL ONCOLOGY

Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China

(2016) Xuefei Li et al.   BMC CANCER

Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion–Positive Metastatic Non–Small-Cell Lung Cancer

(2016) Gerald S. Falchook et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma

(2016) Shiyong Li et al.   Journal of Thoracic Oncology

ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare

(2016) Weijie Zhao et al.   LUNG CANCER

The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis

(2015) Chen Lin et al.   CANCER BIOLOGY & THERAPY

Genomic alterations in lung adenocarcinoma

(2015) Siddhartha Devarakonda et al.   LANCET ONCOLOGY

Present and Future Molecular Testing of Lung Carcinoma

(2014) Sanja Dacic et al.   ADVANCES IN ANATOMIC PATHOLOGY

Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts

(2014) S Li et al.   BRITISH JOURNAL OF CANCER

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer

(2013) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor

(2013) Eamon M. Berge et al.   SEMINARS IN ONCOLOGY

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

(2012) Kristin Bergethon et al.   JOURNAL OF CLINICAL ONCOLOGY

HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation

(2012) Ken Takezawa et al.   Cancer Discovery

Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains

(2011) Chenguang Li et al.   Journal of Thoracic Oncology

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung

(2009) Tae Won Jang et al.   KOREAN JOURNAL OF INTERNAL MEDICINE